07 October 2012

Teva Pharmaceutical Company Inaugurates New $110 Million Sterile Plant in Hungary

Gödöllő, Hungary - 02 October 2012 – Teva Pharmaceutical Company Ltd. announced the inauguration/opening of a new sterile plant today. Due to the 110 million USD investment the new plant is one of the biggest and high-end factories in the world with the annual production capacity of 160-200 million units of injection. 

Opening of the new plant is a further proof of the continuous development and investment to the future and represents Teva’s strong commitment to provide patients with medicines of the highest quality. 

With the 15.000 square meters area and modular way of building the new plant is not only one of the biggest sterile pharmaceutical factories but the most flexible one as well in the world. The production with the 6 independent modules can easily adapt to the market requirements, even 6 different products can be produced at the same time or in case of a huge need for a certain product, modules can sum up their capacities. Exchange from a certain product or packing unit to another one is smooth and fast. Due to the huge production potential and flexibility, the new plant can supply the patients in more than 70 countries, mainly in the U.S., Europe and Far East. As Mihály Kaszás, CEO Teva Pharmaceutical Works Hungary Ltd. highlighted: we are very proud of the investment, but even more proud of our employees, who dreamt of this plant, who planned it, built it, equipped it, and also who will work in it. This plant is the symbol of the harmony between the most up-to-date technology and the people, the creativity and hard work of our human capital. 

Teva is committed towards the highest quality; therefore the best available technology has been used during the construction. The high-end production machines will be managed by 263 well-trained and experienced employees while a strict quality assurance procedure – every 3rd employee is working on the field of quality control - provides the immaculate quality of the medicines. Teva’s primary purpose is not only to meet the current quality requirements of all authorities but to lead the environment and determine the quality level of the future. Because of these efforts the new plant has flawlessly passed one of the most rigorous audits of the world by US Food and Drug Administration. 

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011. 

Source: Teva Pharmaceutical